Back to Continuing Education

Want to buy for someone else? You can purchase a token at check out.

Overview
Goals and Outcomes
Details
Accreditations
Overview
Overview
Only 57% of people with diabetes have well-controlled blood glucose levels. For some people with diabetes, help may already be here in the form of the daily or weekly dosed glucagon-like-peptide-1 receptor agonists exenatide (Byetta, Bydureon), liraglutide (Victoza), dulaglutide (Trulicity), albiglutide (Tanzeum), and the amylin analog pramlintide acetate (Symlin). The U.S. Food and Drug Administration approved the first drugs in these two classes, exenatide and pramlintide, in 2005. Liraglutide was approved in 2010, extended-release exenatide in 2013, and dulaglutide and albiglutide in 2014. Beneficial effects, including weight loss, have led to the subsequent approval of liraglutide (Saxenda) for the treatment of obesity with or without diabetes. Many nurses, dietitians, advanced practitioners, and physicians who work with patients with diabetes have the responsibility of prescribing, educating, and monitoring patients who are using these important treatments.
Goals and Outcomes
Goals and Learning Outcomes
The goal of this continuing education program is to enhance nurses’, dietitians’, advanced practitioners’, and physicians’ ability to care for patients taking new injectable classifications of medications for diabetes. After studying the information presented here, you will be able to:
  • Describe the roles of amylin and the human incretin hormone glucagon-like peptide-1 in regulating blood glucose levels
  • Explain three benefits of GLP-1 receptor agonists and amylin analog injection therapy
  • Discuss three nursing interventions to help patients adjust to and properly use GLP-1 receptor agonists or amylin analog therapy
Details
Course Details

Course Originally Released on : 10/10/2005

CE378-60

Course Author

Susanne J. Pavlovich-Danis

MSN, ARNP-C, CDE, CRRN

Michael G. Danis

BSN, RN, CCRN

Accreditations
Accreditations

NURSES
In support of improving patient care, Relias LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Provider approved by the California Board of Registered Nursing, CEP#13791

Accreditations imageAccreditations image

Disclaimer: Not all courses will provide California Board of Registered Nursing approval. Per California Assembly Bill No. 241, continuing education courses related to direct patient care shall address at least one or a combination of the following:(1) Examples of how implicit bias affects perceptions and treatment decisions of licensees, leading to disparities in health outcomes; or (2) Strategies to address how unintended biases in decision-making may contribute to health care disparities by shaping behavior and producing differences in medical treatment along lines of race, ethnicity, gender identity, sexual orientation, age, socioeconomic status, or other characteristics.

CEBroker
Relias LLC reports to CEBroker for the following boards (Provider # 50-1489): Arkansas State Board Of Nursing, District Of Columbia Board Of Nursing, Florida Board Of Nursing, Georgia Board Of Nursing, New Mexico Board Of Nursing, South Carolina Board Of Nursing and West Virginia Board Of Examiners For Registered Professional Nurses
Please check the licenses/certifications section under my account (after logging in) to make sure you have entered a valid license number. This information is required for correct reporting of your course completions to CE Broker.

Disclosures
None of the planners/faculty, unless otherwise noted, for this educational activity have relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.